Trastuzumab, as an anti-HER2 that is commercially available and that has been approved by the Food and Drug Administration (FDA), can be used as a suitable target ligand for the α-mangostin nano-polymeric system against cancer cells with HER2 expression [22,23]. Here, ERBB2 is linked to cancer.